Shenzhen Edge Medical Co Ltd
2675.HK
Hong Kong Stock Exchange40.00
HKD
+0.30
- -
ISIN
CNE1000062R4
Return %
Stock
S&P500
1Y
-29.33
22.68
3Y
-29.33
70.07
5Y
-29.33
73.87
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jianchen Wang
- Full Time Employees
- 602
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Room 1901, Building 2B Shenzhen Guangdong Province People's Republic of China
- IPO Date
- Jan 8, 2026
- Website
- edgemed.cn
- Similar Companies
- Business
- Shenzhen Edge Medical Co., Ltd. designs, develops, and manufactures surgical robotics systems and related instruments and accessories, focusing on minimally invasive endoscopic procedures and bronchoscopic applications; the company provides Edge Multi-Port Endoscopic Surgical Robot, Edge Single-Port Endoscopic Surgical Robot, Edge Bronchoscope Robot, surgical instruments, maintenance and after-sales support, and related software platforms; it also offers clinical training, model surgical centers, and telesurgery initiatives to expand clinical adoption. Headquartered in Shenzhen, China, the company operates primarily in the Chinese market with expanding international collaborations and clinical deployment programs; it was founded in 2015 and maintains its headquarters in Shenzhen, Guangdong Province. Core products and services include design, development, and manufacture of robot-assisted surgical systems; Edge Endoscopic Surgical Robots (multi-port and single-port configurations); Edge Bronchoscope Robot and related endoscopic instruments; system integration, installation, and commissioning services; ongoing software updates, remote monitoring, and digital platform support; clinical training programs, joint clinical training initiatives, and expansion of application scenarios; post-market service, spare parts, and customer support; partnerships with key medical institutions to advance telesurgery and remote clinical capabilities; research and development activities for instrument and software enhancements; regulatory filings and compliance activities specific to China and international markets. Latest major company changes include strategic expansions of clinical application scenarios and instrument portfolios, increased clinical penetration and adoption through joint training programs and model surgical centers, and ongoing geographic expansion through partnerships and collaborations with top-tier medical institutions; the company reports accelerated growth in robot-assisted surgery volume in China and continued progress in telesurgery initiatives, with a focus on product optimization and service expansion; it also executes reorganizations and governance enhancements to support scale, and actively pursues international cooperation to broaden market access and technology transfer. Additional context: the company operates within the medical devices industry, focusing on surgical robotics and associated instruments; target customers include hospitals, healthcare providers, and surgical centers seeking advanced minimally invasive robotics solutions; geographic footprint centers on China with aims to broaden overseas reach; subsidiaries and potential parent or affiliate relationships include its role within broader Edge Medical corporate group structures and parallel ventures in Asia-Pacific markets.